Skip to main content

Year: 2024

Uniti Group Inc. Reports Third Quarter 2024 Results

Third Quarter Consolidated Bookings Monthly Recurring Revenue of $0.9 Million Increased Over 20% From Prior Year Updates 2024 OutlookNet Income of $12.2 Million for the Third Quarter Net Income of $0.05 Per Diluted Common Share for the Third Quarter AFFO of $0.33 Per Diluted Common Share for the Third QuarterLITTLE ROCK, Ark., Oct. 31, 2024 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its results for the third quarter 2024. “We continue to see solid demand for our mission critical fiber infrastructure at Uniti with consolidated bookings of nearly $1 million in monthly recurring revenue during the quarter. Demand from our Hyperscaler customers also remains strong as we recently announced a long-term award in Montgomery, AL that will add fiber in a strategic market for Uniti that...

Continue reading

Evaxion announces business update and third quarter 2024 financial results

COPENHAGEN, Denmark, October 31, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Since the second quarter 2024 business update, we have continued to execute strongly on our strategy and plans with several major milestones achieved. Key highlights include:Significant expansion of the infectious disease vaccine development collaboration with MSD (tradename of Merck & co., Inc., Rahway, NJ, USA) in a transformative deal for Evaxion Continuously increasing external interest and several ongoing partnerships discussions covering both our platform and pipeline Strong progress in clinical and preclinical...

Continue reading

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62.Declares a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024, payable on November 25, 2024.WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2024. The Company is a leader in the development of innovative magnetic resonance imaging...

Continue reading

Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024

BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial-in number that will permit them to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable...

Continue reading

First Mid Bancshares, Inc. Announces Third Quarter 2024 Results

MATTOON, Ill., Oct. 31, 2024 (GLOBE NEWSWIRE) — First Mid Bancshares, Inc. (NASDAQ: FMBH) (the “Company”) today announced its financial results for the quarter ended September 30, 2024. HighlightsNet income of $19.5 million, or $0.81 diluted EPS Adjusted net income (non-GAAP) of $19.8 million, or $0.83 diluted EPS Loan growth of 1% helped drive second consecutive quarter of net interest income expansion 16.6% year-over-year growth for wealth management and insurance combined Tangible book value per share increased 6.6% in the quarter Board of Directors declares regular quarterly dividend of $0.24 per share“We are pleased to deliver another solid and consistent quarter of financial results,” said Joe Dively, Chairman and Chief Executive Officer. “Healthy growth in loans, core deposits, and noninterest income, along with the...

Continue reading

Stack Capital Group Inc. Reports Q3-24 Financial Results

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK) today announced its financial results for the quarter ended September 30, 2024. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary:Starlink continues to aggressively expand its global reach, having now crossed over 4 million subscribers. With over 6,400 satellites now in operation, Starlink has made impressive progress in signing airlines to its satellite service – United being the most recent, joining other carriers such as Qatar Airways, Air France, Hawaiian Airlines, Air New Zealand and WestJet, to name a few. SpaceX successfully completed its fifth Starship test flight on October 13, 2024, when, for the first time ever, it was able to ‘catch’ its Super Heavy Booster...

Continue reading

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement

Merger to create a company focused on advancing Jade Biosciences’ portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025 Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre-closing private financing, expected to fund operations through 2027 Conference call scheduled for October 31, 2024, at 8:30 AM EDT VANCOUVER, British Columbia and SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE) (“Aerovate”) and Jade Biosciences (“Jade”), a privately held biotechnology company focused on developing best-in-class therapies for autoimmune...

Continue reading

Allegro MicroSystems Reports Second Quarter 2025 Results

– Sales Increased 12% Sequentially to $187 Million – MANCHESTER, N.H., Oct. 31, 2024 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its second quarter ended September 27, 2024. “We delivered results in-line with our commitments. Second quarter sales were $187 million, with sequential growth in both Automotive and Industrial and Other end markets. Non-GAAP EPS was $0.08, at the high end of our outlook,” said Vineet Nargolwala, President and CEO of Allegro. “We are encouraged by the continued demand for our differentiated solutions and the progress made by our customers and partners to rebalance their inventories. We continue to invest for growth...

Continue reading

Norwegian Cruise Line Holdings Reports Strong Third Quarter 2024 Financial Results

Third quarter revenue up ~11% over prior year setting record revenue in a quarter Company beats third quarter guidance across all key metrics and raises full year guidance for fourth time MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd. (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the third quarter ended September 30, 2024 and provided guidance for the fourth quarter and full year 2024. Third Quarter 2024 HighlightsGenerated record third quarter total revenue of $2.8 billion, an ~11% increase compared to the same period in 2023 on 4% capacity growth. GAAP net income was $474.9 million, a 37% increase compared to third quarter 2023, with EPS increasing $0.24, or 34%, to $0.95. Performance...

Continue reading

Enviri Corporation Reports Third Quarter 2024 Results

Third quarter revenues totaled $574 million; organic growth in the quarter was 1% Q3 GAAP operating income of $37 million Adjusted EBITDA in Q3 totaled $85 million, an increase of 3% over the prior-year quarter Completed sale of Reed Minerals, enabling Company to surpass 2024 asset sales goal of $50 to $75 million Refinanced revolving credit and accounts receivable securitization facilities, enhancing financial flexibility 2024 Adjusted EBITDA now expected to be within range of $317 million and $327 million; mid-point lowered 3% to reflect sale of Reed Minerals and other factorsPHILADELPHIA, Oct. 31, 2024 (GLOBE NEWSWIRE) — Enviri Corporation (NYSE: NVRI) today reported third quarter 2024 results. Revenues in the third quarter of 2024 totaled $574 million. GAAP operating income from continuing operations for the third quarter...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.